PDC collaboration to continue
MADISON, Wis. & CASTRES, France—An old relationship is getting a boost as Cellectar Biosciences Inc. and Pierre Fabre extend their existing collaboration to develop phospholipid drug conjugates (PDCs) for oncology. The extension is based on promising preclinical data seen from PDC compounds in a variety of tumor types, and will focus on additional evaluation of the synergistic effects of Cellectar’s phospholipid ethers combined with Pierre Fabre’s novel cytotoxic payloads.
“The extension of our research agreement with Pierre Fabre allows us to further progress the development of an exciting new class of novel targeted antitumor agents and underscores the promise of our next-generation delivery technology. To date, the PDC molecules have demonstrated a clear cancer targeting advantage over the unconjugated payloads,” said Jim Caruso, president and CEO of Cellectar. “We look forward to leveraging the synergistic technologies and skills of our respective organizations to further advance this exciting research.”